BioNTech AG
37Patents
36Active
37Granted
53Portfolio score
Filing activity: Mar 14, 2003 → Feb 19, 2020 · 5 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9476055B2 | Modification of RNA, producing an increased transcript stability and translation efficiency | Human Necessities | 22 | Active |
| US9321808B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | Human Necessities | 22 | Active |
| US9486519B2 | Use of FLT3 ligand for enhancing immune responses in RNA immunization | Chemistry; Metallurgy | 14 | Active |
| US8278262B2 | Use of microproteins as tryptase inhibitors | Chemistry; Metallurgy | 11 | Active |
| US9295717B2 | Vaccine composition comprising 5′-cap modified RNA | Human Necessities | 11 | Active |
| US10106800B2 | Modification of RNA, producing an increased transcript stability and translation efficiency | Human Necessities | 11 | Active |
| US8178653B2 | Recombinant vaccines and use thereof | Chemistry; Metallurgy | 9 | Active |
| US9175088B2 | Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer | Chemistry; Metallurgy | 8 | Active |
| US9533043B2 | Identification of surface-associated antigens for tumor diagnosis and therapy | Physics | 7 | Active |
| US9194004B2 | Identification of surface-associated antigens for tumor diagnosis and therapy | Chemistry; Metallurgy | 6 | Active |
| US9267177B2 | Identification of tumor-associated cell surface antigens for diagnosis and therapy | Physics | 6 | Active |
| US10604568B2 | Diagnosis and therapy of cancer involving cancer stem cells | Physics | 4 | Active |
| US10717780B2 | Agents for treatment of claudin expressing cancer diseases | Chemistry; Metallurgy | 3 | Active |
| US10093736B2 | Agents for treatment of claudin expressing cancer diseases | Chemistry; Metallurgy | 3 | Active |
| US8945923B2 | Antigen-specific clonal expansion of B cells | Chemistry; Metallurgy | 2 | Active |
| US8258258B2 | Dimeric or multimeric microproteins | Human Necessities | 2 | Active |
| US10188712B2 | Tumor antigens for determining cancer therapy | Physics | 2 | Active |
| USD885517S1 | Hydrogen water generator | General | 2 | Active |
| US10980875B2 | Cytotoxic immunostimulating particles and uses thereof | Human Necessities | 2 | Active |
| US10370433B2 | Compositions and methods for diagnosis and treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US8980265B2 | Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) | Chemistry; Metallurgy | 1 | Expired |
| US10253373B2 | Identification of tumor-associated markers for diagnosis and therapy | Chemistry; Metallurgy | 1 | Active |
| US8637006B2 | Recombinant vaccines and use thereof | Chemistry; Metallurgy | 1 | Active |
| US9636414B2 | Particles comprising single stranded RNA and double stranded RNA for immunomodulation | Human Necessities | 1 | Active |
| US10172960B2 | Particles comprising single stranded RNA and double stranded RNA for immunomodulation | Human Necessities | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.